Shares of Exelixis (NASDAQ:EXEL) got hit hard last week after the company said its clinical trial testing Cometriq in prostate cancer would continue. While the continuation of a trial would normally be a non-event -- we'll get the final data before the end of the year -- investors were clearly hoping that the drug would work so well that the trial would be stopped early.

While the trial could still prove successful on the final look at the data, some of the stock price decline is warranted because how well Cometriq works will ultimately determine how well the drug competes against Johnson & Johnson's (NYSE:JNJ) Zytiga and Medivation (NASDAQ:MDVN) and Astellas' Xtandi.

In the following video, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss what the news means for Exelixis, Johnson & Johnson, Medivation, and Astellas.

Prostate cancer has nothing on this $14.4 trillion revolution
Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 trillion industry. Click here to get the full story in this eye-opening report.

Brian Orelli has no position in any stocks mentioned. Max Macaluso owns shares of Exelixis. The Motley Fool recommends and owns shares of Exelixis and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers